Gujarat Kidney IPO Opens Today: Grab Shares at ₹108-114 for Hospital Expansion!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Gujarat Kidney IPO Opens Today: Grab Shares at ₹108-114 for Hospital Expansion!
Overview

Gujarat Kidney and Super Speciality Ltd. is launching its ₹251-crore IPO today, with shares priced between ₹108 and ₹114. The IPO, which closes on Wednesday, aims to raise funds primarily for acquiring Parekhs Hospital and setting up a new hospital in Vadodara, along with robotics equipment purchase and debt repayment. This multi-speciality hospital chain operates seven hospitals across central Gujarat and plans to expand its reach and services through these funds. Anchor investors already committed ₹100 crore.

Gujarat Kidney IPO Opens Today

Gujarat Kidney and Super Speciality Ltd. is set to launch its Initial Public Offering (IPO) today, marking a significant step for the regional healthcare provider. The company aims to raise approximately ₹251 crore through this public issue, with the price band set between ₹108 and ₹114 per share.

The IPO, which will be open for subscription until Wednesday, is structured as a completely fresh issue of equity shares. Funds raised are earmarked for crucial expansion and acquisition plans, including the purchase of Parekhs Hospital and investment in a new facility in Vadodara.

The Core Issue

Gujarat Kidney and Super Speciality Ltd.'s IPO opens today, offering investors a chance to buy shares at ₹108 to ₹114 each. The subscription period concludes on Wednesday. This offering is entirely a fresh issuance of shares, aiming to collect ₹250.8 crore at the upper price limit. The minimum lot size for bids is 128 shares.

Anchor Investor Allocation

Ahead of the public offering, the company successfully raised ₹100 crore from ten anchor investors. These included notable names like Venus Investments, Khandelwal Finance Pvt Ltd, Nexus Global Opportunities Fund, and Sunrise Investment Opportunities Fund. Shares were allocated to these anchor investors at ₹114 per share, the upper end of the price band, demonstrating strong pre-IPO demand.

Use of Proceeds

The capital raised will fuel significant growth initiatives for Gujarat Kidney and Super Speciality Ltd. A key objective is the proposed acquisition of Parekhs Hospital in Ahmedabad, along with contributing to the payment for the already acquired Ashwini Medical Centre. Further funds will support the establishment of a new hospital in Vadodara, including the purchase of advanced robotics equipment. The company also plans to use a portion for debt repayment and future inorganic growth opportunities.

Company Overview

Gujarat Kidney & Super Speciality Ltd. is a mid-sized healthcare chain with a strong presence in central Gujarat. It currently operates seven multi-speciality hospitals and four in-house pharmacies across four cities. The hospital network boasts a total capacity of 490 beds, with 340 beds currently operational, offering both secondary and tertiary care surgical services. The planned acquisition of the 49-bed Parekhs Hospitals will further expand its footprint.

Financial Performance and Outlook

For the financial year 2025, the company reported substantial year-on-year growth in key financial metrics. Revenue surged by 742.9% to ₹40.2 crore, while EBITDA increased by 748.2% to ₹16.5 crore. Profit After Tax (PAT) saw a remarkable rise of 449.2% to ₹9.4 crore.

SBI Securities, acting as an observer, views the company's performance positively but considers it fairly valued. They have assigned a Neutral rating to the IPO.

Market Reaction

The IPO opening is anticipated to attract significant investor interest, particularly from those looking to invest in the growing Indian healthcare sector. The company's focus on regional expansion and acquisition strategy is a key attraction.

Impact

This IPO's success could boost investor confidence in mid-sized regional healthcare players. The expansion plans could lead to increased healthcare accessibility and employment in Gujarat. Potential investors might see this as an opportunity for growth in a sector with consistent demand.
Impact Rating: 7

Difficult Terms Explained

  • IPO (Initial Public Offering): The process where a private company first offers its shares to the public, becoming a publicly-traded company.
  • Fresh Issue: When a company issues new shares to raise capital.
  • Price Band: The range within which the price of a share is offered during an IPO.
  • Lot Size: The minimum number of shares an investor must buy in an IPO.
  • Qualified Institutional Buyers (QIBs): Large institutional investors like mutual funds, foreign institutional investors, etc.
  • Non-Institutional Investors (NIIs): High net-worth individuals and corporate bodies who invest large amounts.
  • Retail Investors: Individual investors who apply for shares up to a certain limit.
  • Anchor Investors: Institutional investors who commit to buying shares before the IPO opens to the public.
  • EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization, a measure of operational profitability.
  • PAT (Profit After Tax): The company's profit remaining after all expenses and taxes have been deducted.
  • YoY (Year-on-Year): A comparison of financial data over two consecutive years.
  • Neutral Rating: An investment recommendation suggesting that the stock is neither a strong buy nor a strong sell.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.